Skin ulcers in systemic sclerosis: Determinants of presence and predictive factors of healing

Journal of the American Academy of Dermatology

Volumn 60, Issue 3, 2009, Pages 426-435

  Alivernini, Stefano ^a   De Santis, Maria ^a   Tolusso, Barbara ^a   Mannocci, Alice ^a   Bosello, Silvia Laura ^a   Peluso, Giusy ^a   Pinnelli, Michela ^a   D'Antona, Graziella ^a   LaTorre, Giuseppe ^a   Ferraccioli, Gianfranco ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ILOPROST; INTERLEUKIN 6; NIFEDIPINE; PENICILLAMINE;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CAPILLAROSCOPY; CARDIOVASCULAR RISK; COMORBIDITY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; FEMALE; FOLLOW UP; HUMAN; INFECTION CONTROL; INFLAMMATION; ITALY; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RISK FACTOR; SKIN INFECTION; SKIN ULCER; SYSTEMIC SCLEROSIS; THROMBOPHILIA; ULCER HEALING;

ADULT; AGED; BIOLOGICAL MARKERS; COMORBIDITY; FEMALE; FOLLOW-UP STUDIES; HUMANS; LOGISTIC MODELS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NAILS; NEOVASCULARIZATION, PHYSIOLOGIC; PREDICTIVE VALUE OF TESTS; RISK FACTORS; SCLERODERMA, SYSTEMIC; SKIN ULCER; SMOKING; WOUND HEALING;

EID: 60149109220     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2008.11.025     Document Type: Article

References (41)

1. Wigley F., and Flavahan N. Raynaud's phenomenon. Rheum Dis Clin North Am 22 (1996) 765-781
2. Hummers L., and Wigley F. Management of Raynaud's phenomenon and digital ischemic lesions in scleroderma. Rheum Dis Clin North Am 29 (2003) 293-313
3. Gryglewski R.J., Botting R.M., and Vane J.R. Mediators produced by the endothelial cell. Hypertension 12 (1988) 530-548
4. Campbell P.M., and LeRoy E.C. Pathogenesis of systemic sclerosis: a vascular hypothesis. Semin Arthritis Rheum 4 (1975) 351-368
5. Kourembanas S., McQuillan L.P., Leung G.K., and Faller D.V. Nitric oxide regulates the expression of vasoconstrictors and growth factors by vascular endothelium under both normoxia and hypoxia. J Clin Invest 92 (1993) 99-104
6. Yamamoto T., Katayama I., and Nishioka K. Nitric oxide production and inducible nitric oxide synthase expression in systemic sclerosis. J Rheumatol 25 (1998) 314-317
7. Kahaleh M.B. Endothelin, an endothelial-dependent vasoconstrictor in scleroderma: enhanced production and profibrotic action. Arthritis Rheum 34 (1991) 978-983
8. McGregor A.R., Watson A., Yunis E., Pandey J.P., Takehara K., Tidwell J.T., et al. Familial clustering of scleroderma spectrum disease. Am J Med 84 (1988) 1023-1032
9. Xu S., Denton C.P., Holmes A., Dashwood M.R., Abraham D.J., and Black C.M. Endothelins: effect on matrix biosynthesis and proliferation in normal and scleroderma fibroblasts. J Cardiovasc Pharmacol 31 Suppl 1 (1998) S360-S363
10. Denton C., and Korn J. Digital ulceration and critical digital ischemia in scleroderma. Scleroderma Care Res 1 (2003) 12-16
11. Merkel P.A., Herlyn K., Martin R.W., Anderson J.J., Mayes M.D., Bell P., et al. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. Arthritis Rheum 46 (2002) 2410-2420
12. Rodnan G., Myerowitz R., and Justh G. Morphologic changes in the digital arteries of patients with progressive systemic sclerosis (scleroderma) and Raynaud phenomenon. Medicine 59 (1980) 393-408
13. Lau C., McLaren M., Saniabadi A., and Belch J. Increased whole blood platelet aggregation in patients with Raynaud's phenomenon with or without systemic sclerosis. Scand J Rheumatol 22 (1993) 97-101
14. Subcommittee for scleroderma criteria of the American Rheumatism Association diagnostic and therapeutic criteria committee: Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23 (1980) 581-590
15. LeRoy E.C., Black C., Fleischmajer R., Jablonska S., Krieg T., Medsger Jr. T.A., et al. Scleroderma (systemic sclerosis): classification, subset and pathogenesis. J Rheumatol 15 (1988) 202-205
16. Akesson A., Fiori G., Krieg T., van den Hoogen F.H., and Seibold J.R. Assessment of skin, joint, tendon and muscle involvement in SSc. Clin Exp Rheumatol 21 Suppl 29 (2003) S5-S8
17. Reveille J.D., Solomon D.H., and ACR ad hoc committee on immunologic testing guidelines. Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70 and nucleolar antibodies. Arthritis Rheum 49 (2003) 399-412
18. National Institutes of Health. Third report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (2001), National Institutes of Health, Bethesda (MD) NIH Publication 01-3670
19. McLaughlin T., Abbasi F., Cheal K., Chu J., Lamendola C., and Reaven G. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med 139 (2003) 802-809
20. American Thoracic Society. Standardization of spirometry-1994 update. Am J Respir Crit Care Med 152 (1995) 1107-1136
21. Kazerooni E., Martinez F., Flint A., Jamadar D.A., Gross B.H., Spizarny D.L., et al. Thin-section CT obtained at 10 mm increments versus three-level thin-section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring. Am J Roentgenol 169 (1997) 977-983
22. De Santis M., Bosello S., La Torre G., Capuano A., Tolusso B., Pagliari G., et al. Functional, radiological and biological markers of alveolitis and infections of the lower respiratory tract in patients with systemic sclerosis. Respir Res 6 (2005) 96
23. Nishimura R.A., Abel M.D., Hatle L.K., and Tajik A.J. Assessment of diastolic function of the heart: background and current applications of Doppler echocardiography, part II: clinical studies. Mayo Clin Proc 64 (1989) 181-204
24. Medsger T.A., Bombardieri S., Czirjak L., Scorza R., Della Rossa A., and Bencivelli W. Assessment of disease severity and prognosis in SSc. Clin Exp Rheumatol 21 (2003) S42-S46
25. Rana B.S., Lim P.O., Naas A.A., Ogston S.A., Newton R.W., Jung R.T., et al. QT interval abnormalities are often present at diagnosis in diabetes and are better predictors of cardiac death than ankle brachial pressure index and autonomic function tests. Heart 91 (2005) 44-50
26. Ferri C., Valentini G., Cozzi F., Sebastiani M., Michelassi C., La Montagna G., et al. Systemic sclerosis study group of the Italian Society of Rheumatology (SIR-GSSSc). Systemic sclerosis: demographic, clinical and serological features and survival in 1012 Italian patients. Medicine 81 (2002) 139-153
27. Mawdsley A.H. Patient perception of UK scleroderma services-results of an anonymous questionnaire. Rheumatology 45 (2006) 1573
28. Gliddon A.E., Dore C.J., and Maddison P.J. Quins Trial Study Group. Influence of clinical features on the health status of patients with limited cutaneous systemic sclerosis. Arthritis Rheum 55 (2006) 473-479
29. Nihtyanova S.I., Brough G.M., Black C.M., and Denton C.P. Clinical burden of digital vasculopathy in limited and diffuse cutaneous systemic sclerosis. Ann Rheum Dis 67 (2008) 120-123
30. Korn J.H., Mayes M., Matucci Cerinic M., Rainisio M., Pope J., Hachulla E., et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 50 (2004) 3985-3993
31. Cutolo M., Sulli A., Pizzorni C., and Accardo S. Nailfold videocapillaroscopy assessment of microvascular damage in systemic sclerosis. J Rheumatol 27 (2000) 155-160
32. Vancheeswaran R., Magoulas T., Efrat G., Wheeler-Jones C., Olsen I., Penny R., et al. Circulating endothelin-1 levels in systemic sclerosis subsets: a marker of fibrosis or vascular dysfunction?. J Rheumatol 21 (1994) 1838-1844
33. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 340 (1999) 115-126
34. Newby A.C. Matrix metalloproteinases regulate migration, proliferation, and death of vascular smooth muscle cells by degrading matrix and non-matrix substrates. Cardiovasc Res 69 (2006) 614-624
35. Distler O., Del Rosso A., Giacomelli R., Cipriani P., Conforti M.L., Guiducci S., et al. Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Res 4 (2002) R11
36. Ferrero S. Is measurement of serum vascular endothelial growth factor reliable in patients with systemic sclerosis?. J Rheumatol 30 (2003) 1529-1533
37. Goodfield M.J., Orchard M.A., and Rowell N.R. Whole blood platelet aggregation and coagulation factors in patients with systemic sclerosis. Br J Haematol 84 (1993) 675-680
38. Awata T., Inoue K., Kurihara S., Ohkubo T., Watanabe M., Inukai K., et al. A common polymorphism in the 5′-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes 51 (2002) 1635-1639
39. Renner W., Kotschan S., Hoffmann C., Obermayer-Pietsch B., and Pilger E. A common 936 C/T mutation in the gene of vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J Vasc Res 37 (2000) 443-448
40. Generini S., and Matucci Cerinic M. Raynaud's phenomenon and vascular disease in systemic sclerosis. Adv Exp Med Biol 455 (1999) 93-100
41. Allanore Y., Seror R., Chevrot A., Kahan A., and Drape J.L. Hand vascular involvement assessed by magnetic resonance angiography in systemic sclerosis. Arthritis Rheum 56 (2007) 2747-2754